Skip to main content

Table 3 Distribution by farm of bacterial pathogens isolated before treatment on day 0 from lower respiratory tract lesions and bronchoalveolar lavage samples, and ranges of minimum inhibitory concentrations (MIC) of marbofloxacin and enrofloxacin

From: Randomised controlled field study to evaluate the efficacy and clinical safety of a single 8 mg/kg injectable dose of marbofloxacin compared with one or two doses of 7.5 mg/kg injectable enrofloxacin for the treatment of Actinobacillus pleuropneumoniae infections in growing-fattening pigs in Europe

   MIC range (μg/mL)
Farm site Marbofloxacin Enrofloxacin n
A. pleuropneumoniae GA 0.03–0.06 0.06–0.12 9
GB 0.03–0.25 0.03–0.25 9
HA 0.06–0.12 0.06–0.12 18
HB 0.03–0.06 0.03–0.06 25
H. somnus GA 0
GB 0.015 0.008 1
HA 0
HB 0.03 0.03 1
P. multocida GA 0
GB 0.015 0.008 1
HA 0.015–0.03 0.008 7
HB 0
B. bronchiseptica GA 0.5 0.5 4
GB 0.25–0.5 0.25–0.5 4
HA 0
HB 0.25 0.5 1
  1. Farm site: Country identification G Germany, H Hungary. A and B indicate different farms within country
  2. MIC concentrations ranges (μg/mL) of the antimicrobial for which all of the isolates were inhibited
  3. n total number of isolates from lung/lower respiratory tract and bronchoalveolar lavage, combined, for which MIC was determined